Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ambrx Biopharma Inc ADR
(NY:
AMAM
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EDT, Mar 16, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ambrx Biopharma Inc ADR
< Previous
1
2
Next >
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
February 10, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
January 10, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END
Via
FinancialNewsMedia
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
From
FN Media Group LLC
Via
GlobeNewswire
AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders
January 08, 2024
From
Halper Sadeh LLC
Via
Business Wire
Ambrx Raises $78 Million and Completes its ATM Program
March 13, 2023
From
Ambrx, Inc.
Via
Business Wire
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
March 07, 2023
Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Ambrx to Commence Trading on Nasdaq
March 06, 2023
From
Ambrx, Inc.
Via
Business Wire
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
March 01, 2023
From
Ambrx, Inc.
Via
Business Wire
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
February 22, 2023
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer
February 16, 2023
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer
February 13, 2023
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development
February 03, 2023
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
December 16, 2022
From
Ambrx Biopharma Inc.
Via
Business Wire
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
December 09, 2022
From
Ambrx Biopharma Inc.
Via
Business Wire
Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70
November 09, 2022
From
Ambrx
Via
Business Wire
Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer
November 01, 2022
From
Ambrx
Via
Business Wire
Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update
August 29, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian
August 16, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors
July 05, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference
June 28, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors
June 06, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences
May 27, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
May 17, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences
May 06, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F
May 02, 2022
From
Ambrx Biopharma Inc.
Via
Business Wire
Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update
April 26, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer
April 25, 2022
From
Ambrx, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.